Palvella Therapeutics, Inc. (PVLA)
Automate Your Wheel Strategy on PVLA
With Tiblio's Option Bot, you can configure your own wheel strategy including PVLA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PVLA
- Rev/Share 0.0
- Book/Share 4.3229
- PB 17.5808
- Debt/Equity 0.0
- CurrentRatio 7.6692
- ROIC -0.381
- MktCap 840534540.0
- FreeCF/Share -1.104
- PFCF -68.885
- PE -34.8075
- Debt/Assets 0.0
- DivYield 0
- ROE -0.6978
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PVLA | Oppenheimer | -- | Outperform | -- | $85 | Sept. 9, 2025 |
| Initiation | PVLA | Raymond James | -- | Outperform | -- | $54 | Aug. 6, 2025 |
| Initiation | PVLA | Truist | -- | Buy | -- | $56 | July 21, 2025 |
| Initiation | PVLA | Chardan Capital Markets | -- | Buy | -- | $50 | April 9, 2025 |
| Initiation | PVLA | Stifel | -- | Buy | -- | $45 | March 26, 2025 |
| Initiation | PVLA | Scotiabank | -- | Sector Outperform | -- | $50 | March 7, 2025 |
| Initiation | PVLA | Canaccord Genuity | -- | Buy | -- | $39 | Feb. 20, 2025 |
| Initiation | PVLA | TD Cowen | -- | Buy | -- | $44 | Feb. 5, 2025 |
| Initiation | PVLA | H.C. Wainwright | -- | Buy | -- | $38 | Dec. 26, 2024 |
| Initiation | PVLA | Cantor Fitzgerald | -- | Overweight | -- | -- | Dec. 18, 2024 |
News
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus) Publication includes a systematic review of 26 studies evaluating the use of rapamycin for the treatment of venous malformations Study authors highlight unmet clinical need for venous malformations and lack of FDA-approved pharmacologic options while advocating for an FDA-approved targeted topical formulation of rapamycin for patients with cutaneous venous malformations WAYNE, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing …
Read More
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies
Read More
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025.
Read More
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued …
Read More
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com.
Read More
About Palvella Therapeutics, Inc. (PVLA)
- IPO Date 2015-01-02
- Website https://palvellatx.com
- Industry Biotechnology
- CEO Wesley H. Kaupinen
- Employees 14